Answers are grounded in this paper and cite their sources.
Background: Outcomes in metastatic melanoma after immune checkpoint inhibition failure are poor with limited long-term survival. There is an urgent need for therapies providing more durable survival. PRAME is an intracellular protein presented on the surface of tumor cells that are targeted by T cell receptors (TCR); PRAME is expressed in 95% of cutaneous melanoma (CM) cells and PRAME expression has been associated with poorer prognosis and shorter survival. Anzu-cel is a PRAME-directed TCR T-cell therapy engineered to recognize intracellular PRAME-derived peptides presented by HLA-A*02:01 on the cell surface and initiate a potent and specific anti-tumor response.
No takes yet. Share an insight, caveat, or question.
Warner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: